Adolescent Scoliosis, Scoliosis
Conditions
Keywords
adolescent idiopathic scoliosis, inflammatory markers, exercise
Brief summary
Inflammatory markers have been analyzed in several diseases of unknown etiology, in the expectation of increasing therapeutic perspectives. This possibility arises from the different levels of tissue injury with low-grade chronic inflammation that have been observed in studies in which the markers were not evaluated traditionally, and today have influenced clinical management. The investigators aimed, therefore, to evaluate the inflammatory markers in patients with AIS before and after aerobic and combined exercise training.
Detailed description
Inflammatory markers have not been evaluated in adolescent idiopathic scoliosis (AIS), but this deformity potentially involves various musculoskeletal structures permanently, which justifies the analysis. A low-grade chronic inflammation may be related to the lower capacity in exercise performance observed in this population, which must be stimulated to perform standardized physical activity.
Interventions
OTHERaerobic exercise
aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
OTHERcombined exercise
aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
DEVICEtreadmill
Sponsors
Fundação de Amparo à Pesquisa do Estado de São Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* thoracic curvature ≥ 45 degrees * indication for surgical treatment of spinal deformity * absence of pulmonary, cardiac, articular or neurological disorder, atopic dermatitis and previous or current allergy * agree part in the research with a assent statement and the person responsible with the consent form and informed
Exclusion criteria
* acknowledged chronic liver or kidney inflammatory disease * use of corticosteroids, acetylsalicylic acid or other nonhormonal anti-inflammatory clinical or laboratorial evidence of infection * severe obesity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| interleukin 8 | change from baseline in interleukin 8 at 3 months | Inflammatory Markers |
| interleukin 1 | change from baseline in interleukin 1 at 3 months | Inflammatory Markers |
| interleukin 6 | change from baseline in interleukin 6 at 3 months | Inflammatory Markers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| diastolic blood pressure in six-minute walk test | change from baseline in diastolic blood pressure at 3 months | analysis of diastolic blood pressure at end of test |
| heart rate in six-minute walk test | change from baseline in heart rate at 3 months | analysis of heart rate at end of test |
| respiratory frequency in six-minute walk test | change from baseline in respiratory frequency at 3 months | analysis of respiratory frequency at end of test |
| Borg scale in six-minute walk test | change from baseline in Borg scale at 3 months | analysis of Borg scale at end of test |
| forced vital capacity (FVC) | change from baseline at 3 months | analyzed in liters or % of predicted of lung capacity variation from baseline at 3 months |
| maximal inspiratory pressure (MIP) | change from baseline at 3 months | analysis of maximal inspiratory pressure variation (cmH2O) |
| distance in six-minute walk test | change from baseline in distance at 3 months | analysis of distance |
| peak expiratory flow | change from baseline at 3 months | peak expiratory flow variation analysis in liters / minute (l/min) |
| forced expiratory volume in the first second (FEV1) | change from baseline at 3 months | analyzed in liters or % of predicted of lung volume variation from baseline at 3 months |
| forced expiratory volume in the first second (FEV1) / forced vital capacity (FVC) | change from baseline at 3 months | Analysis (%) of the relationship between FEV1 and FVC with variation from baseline at 3 months |
| FORCED EXPIRATORY FRACTION (FEF25-75%) | change from baseline at 3 months | analyzed in milliliters (ml) of lung volume variation from baseline at 3 months |
| FORCED EXPIRATORY FRACTION (FEF25-75%) / forced vital capacity (FVC) | change from baseline at 3 months | Analysis (%) of the relationship between FEV1 and FVC with variation from baseline at 3 months |
| maximal expiratory pressure (MEP) | change from baseline at 3 months | analysis of maximal expiratory pressure variation (cmH2O) |
| oxygen saturation in six-minute walk test | change from baseline in oxygen saturation at 3 months | analysis of oxygen saturation at end of test |
| systolic blood pressure in six-minute walk test | change from baseline in systolic blood pressure at 3 months | analysis of systolic blood pressure at end of test |
Countries
Brazil
Outcome results
None listed